# Impact of Evolocumab on the Effects of Clopidogrel in Patients With High On-Treatment Platelet Reactivity

Study · id `cardio:ct-nct03096288` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03096288](<https://clinicaltrials.gov/study/NCT03096288>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03096288

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 259 participants.

## Technical summary

Registry record NCT03096288. Randomized; quadruple masking; primary purpose treatment. Start 2017-10-03 (actual); primary completion 2020-11-02 (actual). Results posted on 2022-02-17.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 259 participants (enrolled count; ClinicalTrials.gov record NCT03096288, source copy `cardio:ctgov-nct03096288-2022-02-17`, retrieved 2026-10-31)
- Started: 2017-10-03 (actual) (ClinicalTrials.gov record NCT03096288, source copy `cardio:ctgov-nct03096288-2022-02-17`, retrieved 2026-10-31)
- Primary completion: 2020-11-02 (actual) (ClinicalTrials.gov record NCT03096288, source copy `cardio:ctgov-nct03096288-2022-02-17`, retrieved 2026-10-31)
- Completion: 2020-11-02 (actual) (ClinicalTrials.gov record NCT03096288, source copy `cardio:ctgov-nct03096288-2022-02-17`, retrieved 2026-10-31)
- Results first posted: 2022-02-17 (ClinicalTrials.gov record NCT03096288, source copy `cardio:ctgov-nct03096288-2022-02-17`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT03096288, source copy `cardio:ctgov-nct03096288-2022-02-17`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03096288-2022-02-17`, retrieved 2026-10-31)

## The registry's words

- Brief title: Impact of Evolocumab on the Effects of Clopidogrel in Patients With High On-Treatment Platelet Reactivity
- Condition: Atherosclerotic Cardiovascular Disease
- Intervention (Drug): Evolocumab
- Intervention (Other): Placebo
- Lead sponsor: University of Florida
- Lead sponsor class: OTHER
- Collaborator: Amgen
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry intervention name matches this record: Evolocumab (`cardio:evolocumab`)
- Registry lists this organization as the lead sponsor: University of Florida (`cardio:org-university-of-florida`)
- Registry lists this organization as a collaborator: Amgen (`cardio:org-amgen`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Impact of evolocumab on the pharmacodynamic profiles of clopidogrel in patients with atherosclerotic cardiovascular disease: a randomised, double-blind, placebo-controlled study (`cardio:pubmed-36602868`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: a0bb3cf77ef94bce76729be39996f35f550fd480d263067bb2280e87bce77cdc
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
